Treatment with anti-cancer drug T-DM1 after pertuzumab is 'good option'

(European School of Oncology) Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T-DM1 -- a drug that combines trastuzumab with an anti-cancer drug called DM1. The research is presented at the Advanced Breast Cancer Fifth International Consensus Conference (ABC5) and published simultaneously in published in Clinical Breast Cancer journal.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: 10 December 2019Source: Cell Reports, Volume 29, Issue 11Author(s): William W. Feng, Owen Wilkins, Scott Bang, Matthew Ung, Jiaqi Li, Jennifer An, Carmen del Genio, Kaleigh Canfield, James DiRenzo, Wendy Wells, Arti Gaur, R. Brooks Robey, Jessie Yanxiang Guo, Ryan L. Powles, Christos Sotiriou, Lajos Pusztai, Maria Febbraio, Chao Cheng, William B. Kinlaw, Manabu KurokawaSummaryAlthough it is established that fatty acid (FA) synthesis supports anabolic growth in cancer, the role of exogenous FA uptake remains elusive. Here we show that, during acquisition of resistance to HER2 inhibition, metabolic rewiring...
Source: Cell Reports - Category: Cytology Source Type: research
A new analysis some 6 years after randomization continues to support dual HER2 blockade plus chemotherapy for HER2-positive early breast cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Women with HER2-positive breast cancer may soon have some brand new treatment options after two experimental drugs performed well in clinical trials.
Source: Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
WEDNESDAY, Dec. 11, 2019 -- Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target. “It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news
Trastuzumab deruxtecan generated durable responses in HER2-positive metastatic breast cancer that had progressed on trastuzumab emtansine and other therapies in a phase 2 study.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Condition:   Breast Cancer Intervention:   Drug: nab-paclitaxel Sponsor:   Chinese Academy of Medical Sciences Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Roche the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Conferences | HER2 | Herceptin